Mannkind (MNKD) Buildings (2024)

Mannkind (MNKD) posted quarterly Buildings of $43.5 million for Q4 2024, little changed quarter-over-quarter from $43.5 million in Q3 2024.

Mannkind (MNKD) Buildings (2024) Analysis & Trends

Mannkind (MNKD) has reported Buildings for 1 consecutive years, with $43.5 million the latest figure, recorded in Q4 2024.

In Q4 2024, Buildings changed N/A year-over-year to $43.5 million; the TTM figure through Dec 2024 stood at $43.5 million (changed N/A YoY), while the FY2024 annual figure was $43.5 million, changed N/A from the prior year.
Buildings steadied at $43.5 million in Q4 2024 per MNKD's latest filing, from $43.5 million in the prior quarter.
Across five years, Buildings topped out at $43.5 million in Q3 2024 and bottomed at $43.4 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mannkind	1.19 Bn	1.08 Bn	94.97 Mn

Download Data